AU Patent

AU2012339753A1 — Modulating certain tyrosine kinases

Assigned to Tesaro Inc · Expires 2014-06-19 · 12y expired

What this patent protects

The present invention provides therapeutic and diagnostic modalities relevant to treating disorders associated with tyrosine kinase actvity.

USPTO Abstract

The present invention provides therapeutic and diagnostic modalities relevant to treating disorders associated with tyrosine kinase actvity.

Drugs covered by this patent

Retevmo (SELPERCATINIB) · Eli Lilly

Patent Metadata

Patent number: AU2012339753A1
Jurisdiction: AU
Classification: —
Expires: 2014-06-19
Drug substance claim: No
Drug product claim: No
Assignee: Tesaro Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.